A Phase 1 interventional study of GZC8072 Tablets and Placebo in Healthy Subjects;Overweight or Obesity, sponsored by Gan & Lee Pharmaceuticals.. Recruiting at 1 site in China. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-30.
Sponsored by Gan & Lee Pharmaceuticals. · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies in Obesity by Gan & Lee Pharmaceuticals — 3 open to participants now, 3 under way, 2 of them phase 3. Obesity · Gan & Lee Pharmaceuticals.
Among the 15 studies in Obesity by Gan & Lee Pharmaceuticals, this one is the 8th largest by planned enrollment, is one of 4 that started in 2026, is one of 8 in phase 1, and was the 15th registered.
11,556 studies on the registry are indexed under Obesity; 2,055 are open to participants now.
Browse Obesity studies →3 of the 15 studies in Obesity by Gan & Lee Pharmaceuticals are open now, in 1 country. Recruiting first, the newest first:
Gan & Lee Pharmaceuticals. · Sites in China
Ages 18+
Gan & Lee Pharmaceuticals. · Sites in China
Ages 18+
By country, each count listing its studies:
Of the 1,346 Obesity studies recruiting now, 379 (28%) set no upper age limit and 863 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 3 · Phase 3 4
First in 2021; this study’s year is marked. 4 started in 2026.
This study's planned enrollment of 126 is above the median of 67 across 9,036 interventional studies indexed under Obesity.
Median enrollment 126 across the 15 interventional studies. Of the 12 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Gan & Lee Pharmaceuticals., one of the names counted as Gan & Lee Pharmaceuticals. Under that name alone:
Gan & Lee Pharmaceuticals. is the lead sponsor of 30 studies on the registry; 15 are open to participants now.
3 of the studies in Obesity by Gan & Lee Pharmaceuticals that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07150975Phase 3Gan & Lee Pharmaceuticals.Phase III Clinical Study Comparing the Efficacy and Safety of GZR18 Injection and Semaglutide (Wegovy®) in Adult Obese or Overweight Subjects | 2027-06-30 |
| NCT07493057Phase 3Gan & Lee Pharmaceuticals.Evaluate the Efficacy and Safety of GZR18 Injection in Obese Subjects With Obstructive Sleep Apnea Not Treated With Positive Airway Pressure (PAP) Therapy | 2027-11-14 |
| NCT07784699Gan & Lee Pharmaceuticals.A Phase 1 Study of GZC8072 Tablets Following a Single Dose in Healthy Study Participants and Multiple Doses in Obese/Overweight Study Participants | 2027-08-18 |
Add all 3 to your calendar (.ics) → With an account.
Among the 15 studies in Obesity by Gan & Lee Pharmaceuticals, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This trial is conducted in China. This study plans to include 2 parts, i.e., a single-dose study and a multiple-dose study:
The single-dose study will be conducted in healthy adult participants to evaluate the safety, tolerability, and pharmacokinetic profile of single doses of GZC8072 Tablets; The multiple-dose study will be conducted in obese or overweight study participants to evaluate the safety, tolerability, pharmacokinetic and pharmacodynamic profiles of multiple doses of GZC8072 Tablets.
The criteria were revised on the registry on Sep 30, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
SAD:
MAD:
Exclusion Criteria:
SAD:
Participants who have any abnormalities in 12-lead , vital signs (blood pressure, respiration, pulse and body temperature), physical examinations, imaging procedures or laboratory tests (hematology, urinalysis, blood biochemistry and coagulation) at screening or predose as judged by the investigator to be unsuitable for participation in this study, or whose laboratory test items at screening or predose meet any of the following criteria:
MAD:
Participants with one of the following prior or existing medical history or conditions:
Participants who have any clinically significant abnormalities in 12-lead ECG, vital signs (blood pressure, respiration, pulse and body temperature), physical examinations, imaging procedures or laboratory tests (hematology, urinalysis, blood biochemistry and coagulation) at screening or predose as judged by the investigator to be unsuitable for participation in this study, or whose laboratory test items at screening, on D-2 or D-1 meet any of the following criteria:
Any condition that, in the investigator's opinion, renders the participant unsuitable for participation in this study, including potential compromise of the participant's rights.
-
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Each participant receives either a single oral dose (SAD) or multiple oral doses (MAD) of GZC8072 Tablets
Drug: GZC8072 Tablets
Each participant receives either a single oral dose (SAD) or multiple oral doses (MAD) of matched placebo.
Drug: Placebo
Oral drug
Oral drug
Incidence of adverse events and serious adverse events
Time frame: SAD:Baseline to Day36 MAD:Baseline to Day57
mmunogenicity: including anti-drug antibodies and neutralizing antibodies to GZC8072.
Time frame: SAD:Baseline to Day36 MAD:Baseline to Day57
Cmax
Time frame: SAD:Baseline to Day36 MAD:Baseline to Day57
AUC0-t
Time frame: SAD:Baseline to Day36 MAD:Baseline to Day57
AUC0-inf
Time frame: SAD:Baseline to Day36 MAD:Baseline to Day57
Tmax
Time frame: SAD:Baseline to Day36 MAD:Baseline to Day57
λ
Time frame: SAD:Baseline to Day36 MAD:Baseline to Day57
t1/2
Time frame: SAD:Baseline to Day36 MAD:Baseline to Day57
CL/F
Time frame: SAD:Baseline to Day36 MAD:Baseline to Day57
Vd
Time frame: SAD:Baseline to Day36 MAD:Baseline to Day57
Cmin(ss)
Time frame: SAD:Baseline to Day36 MAD:Baseline to Day57
Cmax(ss)
Time frame: SAD:Baseline to Day36 MAD:Baseline to Day57
Cav(ss)
Time frame: SAD:Baseline to Day36 MAD:Baseline to Day57
AUC0-τ
Time frame: SAD:Baseline to Day36 MAD:Baseline to Day57
Fasting weight
Time frame: MAD:Baseline to Day57
body mass index (BMI)
Time frame: MAD:Baseline to Day57
waist circumference
Time frame: MAD:Baseline to Day57
FPG
Time frame: MAD:Baseline to Day57
fasting insulin
Time frame: MAD:Baseline to Day57
Started Sep 2026 (actual). Primary completion is estimated for Aug 2027, 11 months after the start.
Of 338 industry-sponsored phase 1 interventional studies under Obesity, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's planned 11 months is above that.
Counting every sponsor, half of 443 studies reached it within 11 months; a quarter within 6 and three quarters within 24.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.